Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that HLX18, a recombinant humanized anti‑PD‑1 monoclonal antibody injection, has received NMPA approval to initiate Phase I clinical trials for various solid tumors – marking dual regulatory progress for the nivolumab (Opdivo®) biosimilar following FDA Phase I approval in December 2025.
FDA approval enables US clinical development; EU pathway possible
Global biosimilar market access vs. China‑only competitors
Market Impact & Outlook
PD‑1 Biosimilar Market Dynamics: Global nivolumab biosimilar market projected US$2‑3 billion annually post‑patent expiry (2028‑2031); China represents 30‑40% of volume with government‑driven price compression; HLX18’s dual FDA/NMPA approval supports ex‑China partnership valuation vs. domestic‑only biosimilars.
Henlius Portfolio Expansion: HLX18 adds to Henlius’s established PD‑1 franchise (serplulimab/Hetronifly – proprietary PD‑1 with differentiated indications); biosimilar strategy provides cost‑competitive option for standard nivolumab indications while serplulimab targets SCLC and differentiated positioning.
Clinical Development Trajectory: Phase I pharmacokinetic/biosimilarity studies 2026 in China and US; Phase III comparative efficacy trials 2027‑2028; potential China approval 2029 assuming positive biosimilarity data; US approval contingent on BMS patent litigation outcomes (potential 2030+).
Fosun Pharma Platform Validation: HLX18 demonstrates Fosun’s independent biosimilar development capabilities beyond licensing; Henlius execution validates Fosun‑Henlius collaboration model for biologics commercialization; potential for additional originator biosimilar partnerships (pembrolizumab, atezolizumab).
Pricing & Access Strategy: China market entry likely at 30‑50% discount to originator nivolumab (current ~RMB40,000‑60,000 annually); NRDL inclusion essential for volume access; global markets (US/EU) potential for 15‑20% discount with automatic substitution policies.
Forward‑Looking Statements This brief contains forward‑looking statements regarding clinical development timelines, biosimilarity demonstration expectations, and commercialization projections for HLX18. Actual results may differ due to patent litigation delays, competitive pricing pressures, and regulatory requirements for extrapolation of indications.-Fineline Info & Tech
By Fineline Cube